Tax Rate Benchmark

The rNPV pro-forma applies a single corporate tax rate to pre-tax operating profit:

The wizard defaults tax_rate to 21% — the US federal statutory corporate rate set by 26 U.S.C. §11(b) (the rate established by the 2017 Tax Cuts and Jobs Act). It is a single, user-overridable input, not a schedule.

Unlike COGS% (modality-keyed) and SG&A% (commercial-model-keyed), the tax rate is deliberately not keyed on the asset at all. Corporate tax is a function of jurisdiction, IP domicile, and net-operating-loss (NOL) position — properties of the legal entity that owns the asset, not of the molecule or how it is sold. A “modality tax rate” or “archetype tax rate” would be a category error. The single statutory anchor is the honest default for a generic single-asset model.

1. Citable and jurisdiction-neutral. 26 U.S.C. §11(b) states the rate as “21 percent of taxable income.” It is a primary legal source, not a company-specific assumption.
2. It avoids baking in a specific company’s offshore-IP structure. Any single real-pharma effective rate embeds that company’s particular IP-domicile and financing arrangements. The statutory rate makes no such assumption, which is the correct posture for a generic asset whose eventual owner is unknown.
3. It is conservative. Real pharma effective rates are materially lower than statutory. Using 21% therefore over-taxes relative to a likely acquirer, which understates NPV — the safe direction of error for a VC sizing an investment.

Large-cap pharma pays far below the 21% statutory rate. The default is the statutory anchor; the effective rates below show why a user modelling a specific acquirer should adjust down.

Table 1. Statutory anchor versus representative FY2024 pharma effective rates. The statutory rate is the default; the effective rates show why a user modelling a specific acquirer should adjust down. Pfizer’s rate is verified to its 10-K; the Amgen and AbbVie figures should be reconciled to each company’s 10-K tax footnote before use in a customer-facing artifact. Source: tax benchmark research file, 2026-05-21.

Why pharma effective ≪ statutory. IP is domiciled in low-tax jurisdictions (Ireland, Switzerland, Puerto Rico); foreign manufacturing income accesses the ~10.5% GILTI rate; the FDII deduction lowers tax on US-held IP export income; and R&D credits reduce the bill further. The result is a structural gap between statutory and effective rates across the sector.

A frequent mistake is to assume a clinical-stage company pays no tax in its early profitable years because of accumulated net operating losses. That is wrong post-2017.

• Modelling an acquirer with offshore IP? Adjust the rate down toward the mid-teens (or lower) to reflect that acquirer’s effective rate. Most large-cap pharma acquirers will tax the asset well below statutory.
• Modelling early profitable years with a large NOL balance? The rate can be reduced, but not to zero — the §172 cap means at least 20% of profit is taxed. Model a partial, not full, shield.
• Want the most conservative (NPV-understating) assumption? Leave it at 21%. That over-taxes relative to a real acquirer and is the safe direction of error.

The 21% default is a transparent anchor, not an estimate of any specific entity’s effective tax rate. It is chosen for citability and conservatism, not for accuracy against a particular acquirer. Override it as soon as the relevant tax posture is known. A reviewer will immediately ask:

• “Statutory or effective? Real pharma pays ~0–16%, not 21%.” (Statutory by design — the conservative, jurisdiction-neutral anchor.)
• “Are you assuming 0% tax for the clinical-stage years?” (No — the §172 cap means at least 20% of profit is taxed even with a large NOL balance.)
• “Whose effective rate would actually apply?” (Unknown for a generic asset; the user adjusts down to model a specific acquirer with offshore IP.)

• Statutory, not effective. 21% is the federal statutory rate. It does not reflect any specific acquirer’s effective rate, which is typically far lower. This is a deliberate, disclosed conservatism, not an oversight.
• US federal only. The anchor excludes US state taxes and any non-US jurisdiction’s corporate rate. A complete tax model for a specific entity would layer those in.
• Effective-rate comparables need 10-K reconciliation. Pfizer’s ~(0.4)% is verified to its 10-K; the Amgen (~11%) and AbbVie (~15%) figures came partly from secondary aggregators and should be reconciled to each company’s 10-K tax footnote before being relied on in a customer-facing artifact.
• NOL position is asset- and entity-specific. The §172 80% cap is general; the actual shield depends on the owning entity’s accumulated NOL balance and profit trajectory, which the default cannot know.

0126 U.S. Code §11 — Tax imposed. §11(b): "21 percent of taxable income" (Tax Cuts and Jobs Act, 2017). Cornell Legal Information Institute.

0226 U.S. Code §172 — Net operating loss deduction. Post-2017: indefinite carryforward, but losses offset only 80% of taxable income. IRS Form 172 instructions.

03Pfizer — FY2024 Form 10-K (SEC). Effective tax rate approximately (0.4)% — a net benefit in the year.

04Amgen — FY2024 results. Effective tax rate approximately 11.3% (verify to the 10-K tax footnote).

05AbbVie — FY2024 quarterly releases and 8-K exhibits (SEC). Adjusted effective tax rate approximately 14.8–16.2% (verify to the 10-K tax footnote).

06Council on Foreign Relations — "American Pharmaceutical Companies Still Aren't Paying Tax in the U.S." (effective-rate divergence via IP domicile, GILTI, FDII).

07Tax Policy Center — TCJA business tax changes (statutory rate cut to 21%, GILTI / FDII / NOL amendments).